← Back to Search

Tyrosine Kinase Inhibitor

pazopanib hydrochloride for Angiosarcoma

Phase 2
Waitlist Available
Led By Margaret von Mehren
Research Sponsored by Fox Chase Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

This trial looks at how well pazopanib hydrochloride works in treating patients with advanced angiosarcoma. Pazopanib hydrochloride may stop the growth of tumor cells.

Eligible Conditions
  • Adult Soft Tissue Sarcoma
  • Angiosarcoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PFS Rate
Response Rate Defined as CR
Response Rate Defined as Partial Response (PR)
Secondary outcome measures
Ability of [F-18] FDG PET/CT as an Imaging Agent in Predicting Efficacy or Early Response as Compared With CT Imaging
Evaluation of Toxicity of Pazopanib Hydrochloride in This Patient Population
Overall Survival of Patients Treated With Pazopanib Hydrochloride

Side effects data

From 2013 Phase 2 trial • 28 Patients • NCT01157091
89%
10020772-Hypertension
61%
10021038-Hyponatremia
57%
10016256-Fatigue
57%
10012727-Diarrhea
57%
10011368-Creatinine increased
57%
10047900-Weight loss
54%
10020949-Hypocalcemia
50%
10028813-Nausea
50%
10020943-Hypoalbuminemia
50%
10049182-White blood cell decreased
46%
10035528-Platelet count decreased
39%
10002272-Anemia
39%
10001675-Alkaline phosphatase increased
36%
10020647-Hyperkalemia
36%
10021005-Hypoglycemia
36%
10003481-Aspartate aminotransferase increased
36%
10025256-Lymphocyte count decreased
32%
10033371-Pain
32%
10002646-Anorexia
25%
10040752-Sinus tachycardia
25%
10003988-Back pain
25%
10000081-Abdominal pain
25%
10033425-Pain in extremity
21%
10019211-Headache
21%
10013573-Dizziness
21%
10047700-Vomiting
21%
10037032-Proteinuria
21%
10010774-Constipation
21%
10029366-Neutrophil count decreased
18%
10020870-Hypertriglyceridemia
18%
10003239-Arthralgia
18%
10001551-Alanine aminotransferase increased
18%
10005364-Blood bilirubin increased
18%
10047896-Weight gain
14%
10016766-Flatulence
14%
10040741-Sinus bradycardia
14%
10020639-Hyperglycemia
14%
10020680-Hypernatremia
14%
10021059-Hypophosphatemia
14%
10028411-Myalgia
14%
10056910-GGT increased
14%
10013963-Dyspnea
11%
10041349-Somnolence
11%
10013911-Dysgeusia
11%
10034620-Peripheral sensory neuropathy
11%
10020587-Hypercalcemia
11%
10016558-Fever
11%
10017577-Gait disturbance
11%
10021018-Hypokalemia
11%
10016750-Flank pain
11%
10002855-Anxiety
11%
10021097-Hypotension
11%
10062501-Non-cardiac chest pain
11%
10046300-Upper respiratory infection
11%
10062572-Generalized muscle weakness
7%
10024264-Lethargy
7%
10015218-Erythema multiforme
7%
10017853-Gastritis
7%
10019611-Hemorrhoids
7%
10038064-Rectal hemorrhage
7%
10038072-Rectal pain
7%
10033987-Paresthesia
7%
10020407-Hot flashes
7%
10040947-Skin ulceration
7%
10008531-Chills
7%
10050068-Edema limbs
7%
10016791-Flu like symptoms
7%
10021028-Hypomagnesemia
7%
10003246-Arthritis
7%
10006002-Bone pain
7%
10022437-Insomnia
7%
10040872-Skin infection
7%
10046571-Urinary tract infection
7%
10008661-Cholesterol high
7%
10055599-Hemoglobin increased
7%
10034263-Pelvic pain
7%
10011224-Cough
4%
hand-foot syndrome symptoms
4%
10034474-Pericardial effusion
4%
10028130-Mucositis oral
4%
10016825-Flushing
4%
10037087-Pruritus
4%
10040868-Skin hypopigmentation
4%
10031009-Oral pain
4%
10041367-Sore throat
4%
10038062-Rectal fistula
4%
10023424-Kidney infection
4%
hand-foot syndrome
4%
10047681-Voice alteration
4%
10069339-Acute kidney injury
4%
10012174-Dehydration
4%
10042112-Stomach pain
4%
10001760-Alopecia
4%
10013786-Dry skin
4%
10033557-Palpitations
4%
10037868-Rash maculo-papular
4%
urothelial carcinoma
4%
10020670-Hypermagnesemia
4%
10029883-Obesity
4%
10054520-Oral dysesthesia
4%
10066874-Gastroesophageal reflux disease
4%
10051272-Facial muscle weakness
4%
piriformis syndrome
4%
10019450-Hematuria
4%
10046539-Urinary frequency
4%
10046555-Urinary retention
4%
10046628-Urine discoloration
4%
10061574-Urinary tract obstruction
4%
aortic sclerosis w/o significant stenosis, mitral annular calcification
4%
10005886-Blurred vision
4%
10002167-Anal pain
4%
10005265-Bloating
4%
10009887-Colitis
4%
10013781-Dry mouth
4%
10062466-Localized edema
4%
10040753-Sinusitis
4%
10061229-Lung infection
4%
bacterial infection
4%
10016173-Fall
4%
10028836-Neck pain
4%
10031282-Osteoporosis
4%
10048677-Buttock pain
4%
10048706-Joint range of motion decreased
4%
10065895-Muscle weakness upper limb
4%
Joint effusion with extensive nodular synovial proliferation
4%
10062225-Urinary tract pain
4%
10046904-Vaginal dryness
4%
10046916-Vaginal inflammation
4%
10028735-Nasal congestion
4%
10036790-Productive cough
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm I

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (enzyme inhibitor therapy)Experimental Treatment5 Interventions
Patients receive pazopanib hydrochloride PO QD. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pazopanib
FDA approved
positron emission tomography
2010
Completed Phase 2
~1370
fludeoxyglucose F 18
2005
Completed Phase 3
~3970
computed tomography
2010
Completed Phase 2
~1200

Find a Location

Who is running the clinical trial?

Fox Chase Cancer CenterLead Sponsor
228 Previous Clinical Trials
37,601 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,687 Previous Clinical Trials
40,930,342 Total Patients Enrolled
Margaret von MehrenPrincipal InvestigatorFox Chase Cancer Center
3 Previous Clinical Trials
85 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
2011. "Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01462630.
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top